Rani Therapeutics (RANI)
(Delayed Data from NSDQ)
$2.93 USD
+0.06 (2.09%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.87 -0.06 (-2.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RANI 2.93 +0.06(2.09%)
Will RANI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RANI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RANI
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates
RANI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
Axsome (AXSM) Hurt by Regulatory Setbacks: Will It Recover?
Other News for RANI
Rani Therapeutics prices securities offering to raise $10 million
Rani Therapeutics to sell 2.8M shares at $3.08 in registered diect offering
Strategic Partnerships and Market Opportunities: Rani Therapeutics’ Promising Outlook in the Obesity Drug Space
Buy Rating Affirmed for Rani Therapeutics Based on Promising Partnerships and Preclinical Data
Buy Rating on Rani Therapeutics: Revolutionizing Obesity Treatment with Oral Drug RT-114